NCT01044277

Brief Summary

This trial is designed to provide evidence of the efficacy of glutathione supplementation and health(GSH) and includes the assessment of both short term and long term effects. Based on previous laboratory animal studies and clinical data, the investigators anticipate that the effects of oral GSH supplementation will be progressive and cumulative. The study will also allow for the evaluation of effects of withdrawal of the supplement on the outcome variables.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
61

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 6, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 7, 2010

Completed
25 days until next milestone

Study Start

First participant enrolled

February 1, 2010

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2011

Completed
3.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
Last Updated

September 6, 2022

Status Verified

August 1, 2022

Enrollment Period

1.6 years

First QC Date

January 6, 2010

Last Update Submit

August 31, 2022

Conditions

Keywords

glutathionegluthathione peroxidasesGSH

Outcome Measures

Primary Outcomes (1)

  • Evaluation of the effect of glutathione on key biomarkers

    Blood glutathione status

    6 to 7 months

Secondary Outcomes (1)

  • Evaluations will be carried out to expand the above comparison by including adjustments for potential prognostic factors.

    6 to 7 months

Study Arms (3)

Group A

EXPERIMENTAL

Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo Other name Gluthathione peroxidases

Drug: Glutathione supplementation

Group B

EXPERIMENTAL

Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo Other name Gluthathione peroxidases

Drug: Gluthathione peroxidases

Group C

PLACEBO COMPARATOR

Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo

Other: Placebo

Interventions

500 mg, two times daily

Also known as: Gluthathione Peroxidates, GSH
Group A

125 mg, two times daily

Also known as: Glutathione supplementation, GSH
Group B
PlaceboOTHER

2 times daily

Also known as: Gluthathione peroxidases, GSH
Group C

Eligibility Criteria

Age30 Years - 79 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy male and females between the ages of 30 and 79 years of age
  • Not taking glutathione as a dietary supplement
  • Not taking high dose antioxidant supplement prior to 1 month
  • Baseline blood glutathione level of \< 1 mmol/L

You may not qualify if:

  • History or evidence of disease including cancer, diabetes, heart disease
  • Subjects who smoke

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, 17033, United States

Location

Related Publications (1)

  • Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015 Mar;54(2):251-63. doi: 10.1007/s00394-014-0706-z. Epub 2014 May 5.

Study Officials

  • John P. Richie, Ph.D.

    Milton S. Hershey Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Public Health Sciences and Pharmacology

Study Record Dates

First Submitted

January 6, 2010

First Posted

January 7, 2010

Study Start

February 1, 2010

Primary Completion

September 1, 2011

Study Completion

October 1, 2014

Last Updated

September 6, 2022

Record last verified: 2022-08

Locations